Global Spatial Genomics Market, By Technology (Fluorescence in situ hybridization (FISH), Microscopy-based Live DNA Imaging, Genome Perturbation Tools, Massively-Parallel Sequencing, Biochemical Techniques, Others), Product (Instruments, Consumables, Software), End-User (Translational Research, Academic Customers, Diagnostic Customers, Pharmaceutical Manufacturer, Government Institutes and Academic Centers, Pharmaceutical and Biotechnology Companies, Contract Research Organizations), Application (Diagnostics and Disease Profiling, Drug Discovery, Others) – Industry Trends and Forecast to 2030.
Spatial Genomics Market Analysis and Size
Breast cancer is one of the most common cancers in the world. Breast cancer has the highest incidence of all cancers in women, according to a study published in January 2020. The study also stated that the annual incidence rate of breast cancer was over 1.6 million cases. This necessitates the use of early diagnostic procedures, which is where the role of particular genomics comes into play.
Data Bridge Market Research analyses that the spatial genomics market which is USD 204.01 million in 2022, is expected to reach USD 490.86 million by 2030, at a CAGR of 11.6% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Spatial Genomics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Technology (Fluorescence in situ hybridization (FISH), Microscopy-based Live DNA Imaging, Genome Perturbation Tools, Massively-Parallel Sequencing, Biochemical Techniques, Others), Product (Instruments, Consumables, Software), End-User (Translational Research, Academic Customers, Diagnostic Customers, Pharmaceutical Manufacturer, Government Institutes and Academic Centers, Pharmaceutical and Biotechnology Companies, Contract Research Organizations), Application (Diagnostics and Disease Profiling, Drug Discovery, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc. (U.S.), 10X Genomics (U.S.), NanoString Technologies Inc. (U.S.), Illumina Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), QIAGEN (Netherlands), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), S2 Genomics, Inc. (U.S.), Seven Bridges Genomics (U.S.), CARTANA AB (Sweden), READCOOR, INC (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), Dovetail Genomics (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Merck & Co., Inc. (Germany), Novo Nordisk A/S (Denmark), Amgen Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Gsk plc (U.K.) and Bayer AG (Germany)
|
|
Market Opportunities
|
|
Market Definition
Spatial genomics is the study of the entire set of genetic commands provided by DNA to detect and diagnose cancer tumour cells. Spatial genomics is used in disease control because it provides quantitative gene expression data. Spatial genomics also provides information on visualizing DNA and RNA mapping into tissue components.
Spatial Genomics Market Dynamics
Drivers
- Rising applications of genomics
The increasing use of genomics and transcriptomics by academic institute researchers is one factor driving market growth. These techniques are widely used for the comprehensive evaluation of a wide range of diseases. For instance, a research institute like Children's Hospital for Philadelphia has experience in both locus discovery and GWAS in both academic and biotech settings. These have established a longitudinal and functional genomics centre to study the genetics of various diseases and the morphology of diseases resulting from genetic disorders such as cancer, diabetes, and Alzheimer's. Furthermore, genomic and transcriptomics technology has broader applications in the sector, such as the Human Cell Atlas. These are the certain factors which propel the market.
- Increasing consumable adoption
Consumable's is significantly boosting the spatial genomics and transcriptomics market in the forecast period with a market share of 57.2% in 2021. The market's expansion is attributed to factors such as high product penetration, increasing consumable adoption, frequent use of kits and reagents for instruments in genomics and transcriptomics, and the wide availability of consumables. These instruments are used to prepare sample specimens for genomic mapping. Furthermore, advancements and new features in the consumables segment are increasing the adoption of biopharmaceuticals and research activities.
Opportunities
- Rising adoption of the transcriptomics
The high adoption of the transcriptomics for single-cell transcriptomics analysis compared to the genomics segment is attributed to the segment's growth. The availability of automated sequencing methods such as laser capture microdissection technique (LCM) to satisfy the requirement for nucleic acid sequencing of biological specimens has accelerated the growth of the spatial genomics market. Furthermore, increased awareness of tissue heterogeneity has fuelled the development of novel sequencing technologies aimed at storing genomic or spatial information for future reference. And it is likely that this factor will propel the market growth during the forecast period.
Restraints/Challenges
- High costs associated with R&D capabilities
High costs associated with R&D capabilities, limited infrastructural facilities, uneven distribution of medical services, a scarcity of skilled medical professionals, and a lack of awareness in backward economies are expected to hamper the market growth. In addition, a lack of favourable reimbursement scenarios and technological penetration in developing economies, the emergence of alternative technologies, limited insurance coverage and regulatory compliance, and a lack of suitable infrastructure in low- and middle-income countries are expected to pose challenges to the market during the forecast period of 2023-2030.
This spatial genomics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the spatial genomics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Spatial Genomics Market
The COVID-19 pandemic had a significant impact on the market. This is because the majority of healthcare resources were directed toward meeting the demand generated by COVID-19 patients. The postponement of non-elective surgeries and non-essential healthcare procedures has slowed the market's growth rate during this pandemic. Shutdown of research facilities and a halt on the projects of pharmaceutical and biotechnological industries also derailed the market growth rate. Furthermore, travel restrictions imposed by lockdown regulations hampered market growth during this period. The post-pandemic period, on the other hand, will help to generate profits and revenues due to an increase in the use of spatial genomics and transcriptomics to profile COVID-19 tissue autopsies, as well as an increase in biomarker identification.
Recent Developments
- In 2020, Cancer Transcriptome Atlas, a new product based on NanoString Technologies' GeoMx Digital Spatial Profiler (DSP) platform, is optimized for readout on Illumina's next-generation sequencing (NGS) technology, is available.
- In 2020, S2 Genomics launched the Singulator 100 System, which automates the processing of solid tissue samples into suspensions of single cells or nuclei with high yields and from small samples for a variety of single-cell biology and genomic analyses.
Global Spatial Genomics Market Scope
The spatial genomics market is segmented on the basis of technology, end-user, product, and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Technology
- Fluorescence in situ hybridization (FISH)
- Microscopy-based Live DNA Imaging
- Genome Perturbation Tools
- Massively-Parallel Sequencing
- Biochemical Techniques
- Others
Product
- Instruments
- Consumables
- Software
End-user
- Translational Research
- Academic Customers
- Diagnostic Customers
- Pharmaceutical Manufacturer
- Government Institutes and Academic Centers
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
Application
- Diagnostics and Disease Profiling
- Drug Discovery
- Others
Spatial Genomics Market Regional Analysis/Insights
The spatial genomics market is analyzed and market size insights and trends are provided by country, technology, end-user, product, and application as referenced above.
The countries covered in the spatial genomics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the spatial genomics market because of the strong base of healthcare facilities, widespread utilization of medications, increasing occurrence of lifestyle diseases, increasing consciousness regarding the essence of maintaining good health and rising number of research activities in this region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, increasing occurrence of lifestyle diseases, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Spatial Genomics Market Share Analysis
The spatial genomics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to spatial genomics market.
Some of the major players operating in the spatial genomics market are:
- Thermo Fisher Scientific Inc. (U.S.)
- 10X Genomics (U.S.)
- NanoString Technologies Inc. (U.S.)
- Illumina Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- QIAGEN (Netherlands)
- Agilent Technologies, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- S2 Genomics, Inc. (U.S.)
- Seven Bridges Genomics (U.S.)
- CARTANA AB (Sweden)
- READCOOR, INC (U.S.)
- Advanced Cell Diagnostics, Inc. (U.S.)
- Dovetail Genomics (U.S.)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
- Merck & Co., Inc. (Germany)
- Novo Nordisk A/S (Denmark)
- Amgen Inc. (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Gsk plc (U.K.)
- Bayer AG (Germany)
SKU-